Compare NGS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGS | ETON |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.6M | 1.3B |
| IPO Year | 2006 | 2018 |
| Metric | NGS | ETON |
|---|---|---|
| Price | $37.76 | $57.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $40.67 | $39.33 |
| AVG Volume (30 Days) | 96.8K | ★ 521.1K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 14.60 | N/A |
| EPS | ★ 0.83 | 0.41 |
| Revenue | ★ $172,315,000.00 | $79,950,000.00 |
| Revenue This Year | $15.05 | $40.90 |
| Revenue Next Year | $9.52 | $47.23 |
| P/E Ratio | ★ $45.63 | $139.22 |
| Revenue Growth | 9.94 | ★ 104.94 |
| 52 Week Low | $25.53 | $14.27 |
| 52 Week High | $44.61 | $66.37 |
| Indicator | NGS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 54.99 |
| Support Level | $36.66 | $15.66 |
| Resistance Level | $39.56 | $66.37 |
| Average True Range (ATR) | 1.09 | 2.77 |
| MACD | 0.36 | -1.07 |
| Stochastic Oscillator | 61.84 | 19.20 |
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. It operates in one reporting segment. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.